Literature DB >> 25599615

ROS and energy metabolism in cancer cells: alliance for fast growth.

Sang Won Kang1, Sunmi Lee, Eun Kyung Lee.   

Abstract

In normal cells, the cellular reactive oxygen species (ROS) level is proportional to the activity of mitochondrial electron transport and tightly controlled by endogenous antioxidant system. However, energy metabolism and ROS homeostasis in cancer cells are much different from those in normal cells. For example, a majority of cellular glucose is metabolized through aerobic glycolysis ("Warburg effect") and the pentose phosphate pathway. Cancer cells harbor functional mitochondria, but many mutations in nuclear DNA-encoded mitochondrial genes and mitochondrial genome result in the mitochondrial metabolic reprogramming. The other characteristic of cancer cells is to maintain much higher ROS level than normal cells. Ironically, cancer cells overexpress the ROS-producing NADPH oxidase and the ROS-eliminating antioxidant enzymes, both of which enzyme systems share NADPH as a reducing power source. In this article, we review the complex connection between ROS and energy metabolisms in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599615     DOI: 10.1007/s12272-015-0550-6

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  37 in total

1.  Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

Authors:  Norelle C Wildburger; Shiyue Zhou; Lauren G Zacharias; Roger A Kroes; Joseph R Moskal; Mary Schmidt; Parvin Mirzaei; Joy Gumin; Frederick F Lang; Yehia Mechref; Carol L Nilsson
Journal:  J Proteome Res       Date:  2015-08-04       Impact factor: 4.466

2.  Reactive Oxygen Species Synergize To Potently and Selectively Induce Cancer Cell Death.

Authors:  Hyang Yeon Lee; Elizabeth I Parkinson; Carlotta Granchi; Ilaria Paterni; Dipak Panigrahy; Pankaj Seth; Filippo Minutolo; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2017-04-07       Impact factor: 5.100

3.  Grainyhead-like 2 Reverses the Metabolic Changes Induced by the Oncogenic Epithelial-Mesenchymal Transition: Effects on Anoikis.

Authors:  Joshua C Farris; Phillip M Pifer; Liang Zheng; Eyal Gottlieb; James Denvir; Steven M Frisch
Journal:  Mol Cancer Res       Date:  2016-04-15       Impact factor: 5.852

4.  Procyanidin B2 3,3″-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.

Authors:  Rahul Kumar; Gagan Deep; Michael F Wempe; Joseph Surek; Amit Kumar; Rajesh Agarwal; Chapla Agarwal
Journal:  Mol Carcinog       Date:  2017-09-22       Impact factor: 4.784

5.  REX technologies for profiling and decoding the electrophile signaling axes mediated by Rosetta Stone proteins.

Authors:  Marcus J C Long; Daniel A Urul; Yimon Aye
Journal:  Methods Enzymol       Date:  2019-03-14       Impact factor: 1.600

Review 6.  Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.

Authors:  Luksana Chaiswing; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2018-02-21       Impact factor: 8.401

7.  Functional Metabolomics and Chemoproteomics Approaches Reveal Novel Metabolic Targets for Anticancer Therapy.

Authors:  Chang Shao; Wenjie Lu; Haiping Hao; Hui Ye
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Extracellular Vesicles and Cancer Therapy: Insights into the Role of Oxidative Stress.

Authors:  Jenni Ho; Luksana Chaiswing; Daret K St Clair
Journal:  Antioxidants (Basel)       Date:  2022-06-17

9.  Sulfur Metabolism Under Stress.

Authors:  Colin G Miller; Edward E Schmidt
Journal:  Antioxid Redox Signal       Date:  2020-08-14       Impact factor: 8.401

10.  Ginsenoside-Rg2 exerts anti-cancer effects through ROS-mediated AMPK activation associated mitochondrial damage and oxidation in MCF-7 cells.

Authors:  Hyesu Jeon; Yujin Jin; Chang-Seon Myung; Kyung-Sun Heo
Journal:  Arch Pharm Res       Date:  2021-07-24       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.